Parkinson’s disease, epilepsy, and amyotrophic lateral sclerosis—emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors

Vukolova, Marina N.; Yen, Laura Y.; Khmyz, Margarita I.; Sobolevsky, Alexander I.; Yelshanskaya, Maria V.

doi:10.3389/fcell.2023.1252953

Cited by 3 publications

(1 citation statement)

References 205 publications

(194 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutamatergic neurotransmission is responsible for many cognitive, motor, sensory, and autonomic nervous activities [ 220 , 221 , 222 ]. Neuroexcitotoxicity induced by glutamate has been demonstrated in a number of neurological and psychiatric disorders, including PD [ 223 , 224 , 225 , 226 , 227 ], epilepsy [ 228 , 229 ], traumatic brain injury [ 230 , 231 ], MS [ 232 , 233 , 234 ], AD [ 223 , 224 , 235 , 236 ], HD [ 223 , 237 , 238 , 239 ], ALS [ 223 , 239 , 240 ], etc.…”

Section: Resultsmentioning

confidence: 99%

L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review

Wang,

Pan,

Liu

et al. 2024

Nutrients

View full text Add to dashboard Cite

L-carnitine (LC), a vital nutritional supplement, plays a crucial role in myocardial health and exhibits significant cardioprotective effects. LC, being the principal constituent of clinical-grade supplements, finds extensive application in the recovery and treatment of diverse cardiovascular and cerebrovascular disorders. However, controversies persist regarding the utilization of LC in nervous system diseases, with varying effects observed across numerous mental and neurological disorders. This article primarily aims to gather and analyze database information to comprehensively summarize the therapeutic potential of LC in patients suffering from nervous system diseases while providing valuable references for further research. Methods: A comprehensive search was conducted in PubMed, Web Of Science, Embase, Ovid Medline, Cochrane Library and Clinicaltrials.gov databases. The literature pertaining to the impact of LC supplementation on neurological or psychiatric disorders in patients was reviewed up until November 2023. No language or temporal restrictions were imposed on the search. Results: A total of 1479 articles were retrieved, and after the removal of duplicates through both automated and manual exclusion processes, 962 articles remained. Subsequently, a meticulous re-screening led to the identification of 60 relevant articles. Among these, there were 12 publications focusing on hepatic encephalopathy (HE), while neurodegenerative diseases (NDs) and peripheral nervous system diseases (PNSDs) were represented by 9 and 6 articles, respectively. Additionally, stroke was addressed in five publications, whereas Raynaud’s syndrome (RS) and cognitive disorder (CD) each had three dedicated studies. Furthermore, migraine, depression, and amyotrophic lateral sclerosis (ALS) each accounted for two publications. Lastly, one article was found for other symptoms under investigation. Conclusion: In summary, LC has demonstrated favorable therapeutic effects in the management of HE, Alzheimer’s disease (AD), carpal tunnel syndrome (CTS), CD, migraine, neurofibromatosis (NF), PNSDs, RS, and stroke. However, its efficacy appears to be relatively limited in conditions such as ALS, ataxia, attention deficit hyperactivity disorder (ADHD), depression, chronic fatigue syndrome (CFS), Down syndrome (DS), and sciatica.

show abstract

Section: Resultsmentioning

confidence: 99%

L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review

Wang,

Pan,

Liu

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

The Role of Ferroptosis in Amyotrophic Lateral Sclerosis Treatment

Wang,

Zhang,

Bai

et al. 2024

Neurochem Res

View full text Add to dashboard Cite

Inhibition of AMPARs ameliorates atrial inflammation and vulnerability to atrial fibrillation in rats with anxiety disorders

Zou,

Liu,

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Previous studies have found that anxiety disorders may increase the incidence of atrial fibrillation (AF). More and more studies have shown that AMPARs are involved in the occurrence and development of cardiovascular diseases. However, the role of AMPARs in AF associated with anxiety disorder remains unclear. The aim of this study was to investigate the effect of AMPARs on atrial fibrillation susceptibility in rats with anxiety disorder and its possible mechanism. The anxiety disorder rat model was established by unpredictable empty bottle stimulation, and was treated with AMPARs agonist and antagonist. Our results showed that AMPARs antagonist treatment significantly reduced sympathetic activity, improved heart rate variability, shortened action potential duration, prolonged effective refractory period, reduced AF induction rate, and improved cardiac electrical remodeling and the expression of inflammatory factors. In addition, inhibition of AMPARs reduced the phosphorylation of IκBα and p65. Our experimental results suggest that inhibition of AMPARs can reduce autonomic remodeling, improve atrial electrical remodeling and suppress myocardial inflammation, which provides a potential therapeutic strategy for the treatment of AF associated with anxiety disorder.

show abstract

Parkinson’s disease, epilepsy, and amyotrophic lateral sclerosis—emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors

Cited by 3 publications

References 205 publications

L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review

L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review

The Role of Ferroptosis in Amyotrophic Lateral Sclerosis Treatment

Inhibition of AMPARs ameliorates atrial inflammation and vulnerability to atrial fibrillation in rats with anxiety disorders

Contact Info

Product

Resources

About